---
title: "Jenscare Scientific Co., Ltd. (09877.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/09877.HK.md"
symbol: "09877.HK"
name: "Jenscare Scientific Co., Ltd."
industry: "Health Care Equipment"
---

# Jenscare Scientific Co., Ltd. (09877.HK)

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Location | HK Market |
| Website | [www.jenscare.com](https://www.jenscare.com) |

## Company Profile

Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) pro...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:11.000Z

**Overall: C (0.59)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 18 / 26 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 17.79% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.60 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3.43B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 14.56M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -25.09% | E |
| Profit Margin | -1823.43% | E |
| Gross Margin | 88.09% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | C |
| Net Profit YoY | 17.79% | B |
| Total Assets YoY | -16.21% | E |
| Net Assets YoY | -18.63% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -5.48% | D |
| OCF YoY | 0.00% | C |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.01 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 11.64% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Jenscare Scientific Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-25.09%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1823.43%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "88.09%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "17.79%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-16.21%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-18.63%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-5.48%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "11.64%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ANGELALIGN (HK.6699) | B | A | C | B | B | B |
| 02 | ZYLOXTB (HK.2190) | B | A | D | A | B | B |
| 03 | AK MEDICAL (HK.1789) | B | A | C | B | B | B |
| 04 | SCIENTECH (HK.2291) | A | B | D | A | B | B |
| 05 | MODERN DENTAL (HK.3600) | A | B | B | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -12.79 | 20/27 | - | - | - |
| PB | 3.60 | 21/27 | 3.97 | 3.60 | 2.52 |
| PS (TTM) | 116.60 | 27/27 | 147.35 | 126.24 | 117.03 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2024-10-06T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.23 |

## References

- [Company Overview](https://longbridge.com/en/quote/09877.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/09877.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/09877.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.